View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 22, 2020updated 12 Jul 2022 11:48am

Amarin supports trial on effects of Vascepa in Covid-19 treatment

Biopharmaceutical firm Amarin has announced support for a clinical trial to investigate the effects of Vascepa on inflammatory biomarkers and other patient outcomes in patients with coronavirus (Covid-19) infection.

Biopharmaceutical firm Amarin announced support for a clinical trial to investigate the effects of Vascepa on inflammatory biomarkers and other patient outcomes in patients with coronavirus (Covid-19) infection.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Vascepa capsules, solely comprising the active ingredient icosapent ethyl (IPE), are the first-and-only prescription treatment approved by the Food and Drug Administration (FDA).

The trial is sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group and is being led by University of Toronto professor Dr Subodh Verma and Harvard Medical School professor Dr Deepak Bhatt.

The primary endpoint of the trial is the effect of Vascepa compared to usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults diagnosed with Covid-19-positive.

The clinical study is also designed to assess rates and severity of Covid-19 infection in this high-risk group.

Deepak Bhatt stated: “We believe that this pilot study may provide important information on whether, how, and if icosapent ethyl has biological activity that could have beneficial effects in mitigating severity in Covid-19 infection.

“If a positive signal is achieved in this study, larger, more definitive studies could then be considered. This pilot will also provide further insight into the effects of icosapent ethyl on various biomarkers, as well as valuable information about higher loading doses of this drug.”

According to Amarin, the clinical effects of Vascepa are multi-factorial.

The company said that multiple mechanisms of action associated with Vascepa from clinical and mechanistic studies support the rationale to analyse its effects in Covid-19-infected patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena